New Concepts in Diabetes and Its Treatment - part 3 docx

... 2,709 38 3, 070Average 74 23. 5 1, 736 30 .6 2,257 35 .3 2,605 40.0 2,952Women18 30 years old 56 24 1 ,32 3 31 1,720 35 1,985 40 2,24960 23 1 ,38 3 30 1,798 35 2,074 39 2 ,35 164 23 1,442 29 1,875 34 ... 1,814 31 .9 2 ,35 8 36 .8 2,721 41.7 3, 084 31 –60 years old 68 25 1,667 32 2,167 37 2,500 42 2, 833 72 24 1,7 13 31 2,227 36 2,570 40 2,91276 23 1,760 30 2,288 35 2, 639 39 2,99180 23 1,806 29 2 ,34 8 34 ... kcal/dayMen18 30 years old 68 25 1,7 23 33 2,240 38 2,585 43 2,92972 25 1,784 32 2 ,31 9 37 2,675 42 3, 032 76 24 1,844 32 2 ,39 7 36 2,766 41 3, 135 80 24 1,905 31 2,476 36 2,857 40 3, 238 Average 74...

... MAP-K>mitogen-activated protein kinase; PC-1>an ecto-proteinkinase probably interfering with insulin receptor tyrosine kinase; PI3-K>phosphatidyl-inositol -3 kinase; PIP2>phosphatidylinositol-4,5-P; PKA>protein ... threonine (the serine/threonine-spe-cific protein kinases). The receptor -subunit can be phosphorylated on serine,threonine and tyrosine residues and possesses intrinsic protein-tyrosine kinaseactivity. ... reduce fast-ing hyperglycemia and insulinemia by improving insulin sensitivity in skeletal53Insulin Resistance and Its Relevance to Treatment and in nephropathic diabetic patients.A newly developed...

... (lean and/ or trained sub-jects) and elevated (?15 U/ml) in insulin-resistant subjects. It should bepointed out that an apparent normal insulin level in insulin-resistant diabeticsubjects indicates ... IP 3 >inositol-1,4,5-trisphosphate; M 3 >a type of muscarinic re-ceptor; PIP2>phosphatidylinositol-4,5-P; PKA>protein kinase A; PKC>protein kinase C;PLC>phospholipase C.23Insulin ... changed in type 2patients, suggesting preserved -cell sensitivity in these patients.Insulin Secretion in Type 2 Diabetes Both impaired insulin action (insulin resistance) and reduced insulin secre-tion...

... Regular and intermediate-acting insulin before breakfast, regular insu-lin before lunch and supper, and intermediate-acting insulin at bedtime (4daily insulin doses).(d) Regular insulin before ... accepted.81Insulin Treatment in Type 1 and Type 2 Diabetes Table 5. Factors in uencing the formation of insulin antibodiesInsulin species (human insulin is less immunogenic than animal insulins)Insulin ... injections,regular and intermediate-acting insulin before breakfast, regular insulin beforesupper and intermediate-acting insulin at bedtime. This 3 times daily insulindose regimen is useful in diabetic...

... PKC--selectiveinhibitor, LY -3 3 3 531 . LY -3 3 3 531 is a competitive, reversible inhibitor of PKC-1 and PKC-2, with a 50-foldlesser effect on other PKC isoenzymes. In studies over 2–8 weeks in ... simultaneous determinations every4–6 h of glycemia, insulinemia and C-peptide during fasting periods of 24,48 and 72 h. In insulinoma, glycemia falls while C-peptide and insulinemiaremain near-unmodified. ... as aminoguanidine in preventing diabetes- related decreases in rat tailcollagen solubility in vivo. Our own group has evaluated 2 , 3- diaminophena-zine, another inhibitor of AGE formation, and...